260 related articles for article (PubMed ID: 18405850)
1. Snapshot PK: a rapid rodent in vivo preclinical screening approach.
Liu B; Chang J; Gordon WP; Isbell J; Zhou Y; Tuntland T
Drug Discov Today; 2008 Apr; 13(7-8):360-7. PubMed ID: 18405850
[TBL] [Abstract][Full Text] [Related]
2. A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery.
Li C; Liu B; Chang J; Groessl T; Zimmerman M; He YQ; Isbell J; Tuntland T
Drug Discov Today; 2013 Jan; 18(1-2):71-8. PubMed ID: 22982770
[TBL] [Abstract][Full Text] [Related]
3. Fast mouse PK (Fast PK): a rapid screening method to increase pharmacokinetic throughput in pre-clinical drug discovery.
Reddy J; Madishetti S; Vachaspati PR
Eur J Pharm Sci; 2012 Sep; 47(2):444-50. PubMed ID: 22789493
[TBL] [Abstract][Full Text] [Related]
4. Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery.
Korfmacher WA; Cox KA; Ng KJ; Veals J; Hsieh Y; Wainhaus S; Broske L; Prelusky D; Nomeir A; White RE
Rapid Commun Mass Spectrom; 2001; 15(5):335-40. PubMed ID: 11241763
[TBL] [Abstract][Full Text] [Related]
5. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
Beaumont K; Smith DA
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
[TBL] [Abstract][Full Text] [Related]
6. In vivo rat PK profiling in drug discovery: new challenges.
Zonzini L; Bianchi F; Cesari N; Sartori M
Expert Opin Drug Discov; 2010 Nov; 5(11):1031-7. PubMed ID: 22827743
[TBL] [Abstract][Full Text] [Related]
7. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
Lüpfert C; Reichel A
Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
[TBL] [Abstract][Full Text] [Related]
8. Liquid chromatography/tandem mass spectrometric quantification with metabolite screening as a strategy to enhance the early drug discovery process.
Tiller PR; Romanyshyn LA
Rapid Commun Mass Spectrom; 2002; 16(12):1225-31. PubMed ID: 12112275
[TBL] [Abstract][Full Text] [Related]
9. Moderate correlations of in vitro versus in vivo pharmacokinetics questioning the need of early microsomal stability testing.
Schrezenmeier E; Zollmann FS; Seidel K; Böhm C; Schmerbach K; Kroh M; Kirsch S; Klare S; Bernhard S; Kappert K; Goldin-Lang P; Skuballa W; Unger T; Funke-Kaiser H
Pharmacology; 2012; 90(5-6):307-15. PubMed ID: 23037500
[TBL] [Abstract][Full Text] [Related]
10. Applications of high-throughput ADME in drug discovery.
Kassel DB
Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
[TBL] [Abstract][Full Text] [Related]
11. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens.
Caldwell GW
Curr Opin Drug Discov Devel; 2000 Jan; 3(1):30-41. PubMed ID: 19649835
[TBL] [Abstract][Full Text] [Related]
12. Current and future trends in the application of HPLC-MS to metabolite-identification studies.
Castro-Perez JM
Drug Discov Today; 2007 Mar; 12(5-6):249-56. PubMed ID: 17331890
[TBL] [Abstract][Full Text] [Related]
13. Correct assessment of new compounds using in vivo screening models can reduce false positives.
Bueters TJ; Hoogstraate J; Visser SA
Drug Discov Today; 2009 Jan; 14(1-2):89-94. PubMed ID: 18840543
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study.
Germani M; Crivori P; Rocchetti M; Burton PS; Wilson AG; Smith ME; Poggesi I
Eur J Pharm Sci; 2007 Jul; 31(3-4):190-201. PubMed ID: 17481865
[TBL] [Abstract][Full Text] [Related]
15. Streamlining lead discovery by aligning in silico and high-throughput screening.
Davies JW; Glick M; Jenkins JL
Curr Opin Chem Biol; 2006 Aug; 10(4):343-51. PubMed ID: 16822701
[TBL] [Abstract][Full Text] [Related]
16. PK/PD modelling and simulations: utility in drug development.
Rajman I
Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
[TBL] [Abstract][Full Text] [Related]
17. Preclinical formulations for discovery and toxicology: physicochemical challenges.
Neervannan S
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):715-31. PubMed ID: 17014391
[TBL] [Abstract][Full Text] [Related]
18. Strategies for dealing with reactive intermediates in drug discovery and development.
Nassar AE; Lopez-Anaya A
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
[TBL] [Abstract][Full Text] [Related]
19. Molecular imaging strategies for drug discovery and development.
Gross S; Piwnica-Worms D
Curr Opin Chem Biol; 2006 Aug; 10(4):334-42. PubMed ID: 16822702
[TBL] [Abstract][Full Text] [Related]
20. Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug-drug interactions.
Ward KW; Coon DJ; Magiera D; Bhadresa S; Struharik M; Lawrence MS
Xenobiotica; 2009 Mar; 39(3):266-72. PubMed ID: 19280525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
